Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2012

View Archived Issues

EMERGE study results presented for pegylated interferon lambda-1a

Gene therapy rescues retinal degeneration in Prom1 knockout mice

Gene therapy shows promise for retinal degeneration

GlaxoSmithKline patents novel CRAC inhibitors

U.S. team develops new immunogenic polypeptides for HIV infection

Lupin synthesizes novel voltage-gated sodium channel blockers

Merck KGaA designs new MetAP 2 inhibitors

Presidio Pharmaceuticals discloses new compounds targeting NS5A protein

Biomarkers of inflammation are associated with AMD severity

S1 Biopharma expands focus

Early clinical data for ABT-267 monotherapy and combination treatment shows promise

Biovest plans to seek European marketing approval for cancer vaccine

New phase III Lu-AA-21004 data in MDD support planned regulatory filings

Bristol-Myers Squibb establishes first discovery collaboration in China

Newron completes phase III program for safinamide, signs new licensing agreement

Maxygen to receive payment from Bayer HealthCare for factor VIIa program

Resminostat enters clinical development in Japan

KineMed and CHDI Foundation enter biomarker collaboration

Livatag begins phase III trial for liver cancer

Fibrocell Science submits protocol to FDA for azficel-T study

Cyclacel gives update on phase II/III sapacitabine study

IDRI finds partner for tuberculosis vaccine candidate

Scil Proteins enters into collaboration with Ono Pharmaceutical

L-DOS-47 begins phase I/II study for NSCLC

Furiex enters into licensing agreements for Priligy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...